1 *Pex11*β knockdown decreases peroxisome abundance and reverses the inhibitory

2 effect of palmitate on pancreatic beta-cell function.

- 3
- 4 Helen R Blair¹, Cara Tomas¹, Audrey E Brown¹, Satomi Miwa², Alan Health³, Alison Russell³,
- 5 Michael-van Ginkel³, David Gunn³, Mark Walker^{1*}
- 6
- 7 1. Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle
- 8 University, Newcastle upon Tyne, UK
- 9 2. Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon
- 10 Tyne, UK
- 11 3. Unilever Discover, Colworth Science Park, Sharnbrook, Bedford, UK.
- 12
- 13
- 14 *Corresponding Author:
- 15 Mark.walker@ncl.ac.uk
- 16

17 Aims

- 18 Reactive oxygen species generated by the peroxisomes and mitochondria contribute to
- 19 lipotoxicity in pancreatic beta-cells. Through targeted *Pex11*β knockdown and peroxisome
- 20 depletion, our aim was to investigate the specific contribution of peroxisomes to palmitate
- 21 mediated pancreatic beta-cell dysfunction.

22 Methods

- 23 MIN6 cells were transfected with probes targeted against *Pex11* β , a regulator of peroxisome
- abundance, or with scrambled control probes. Peroxisome abundance was measured by
- 25 PMP-70 protein expression. 48hrs post transfection, cells were incubated with or without
- 26 250µM palmitate for a further 48hrs before measurement of reactive oxygen species,
- 27 mitochondrial respiratory function, and glucose stimulated insulin secretion.
- 28 Results
- 29 *Pex11*β knockdown decreased target gene expression by more than 80% compared with the
- 30 scrambled control (P<0.001), leading to decreased PMP-70 expression (p<0.01). *Pex11*β
- 31 knockdown decreased palmitate mediated generation of reactive oxygen species (P<0.001),
- 32 but with no effect on mitochondrial respiratory function. At 25mM glucose, palmitate
- treatment decreased insulin secretion in the control cells (2.54±0.25 vs 7.07±0.83
- 34 [mean±SEM] ng/hr/µg protein; P<0.001), with a similar pattern in the *Pex11* β knockdown
- 35 cells. However, in the presence of palmitate, insulin secretion was significantly higher in the
- 36 *Pex11*β knockdown versus control cells (4.04±0.46 vs 2.54±0.25 ng/hr/µg protein; p<0.05).
- 37 Conclusion
- 38 *Pex11*β knockdown decreased peroxisome abundance, decreased palmitate mediated ROS
- 39 generation, and reversed the inhibitory effect of palmitate on insulin secretion. These
- 40 findings highlight a specific and independent role for peroxisomes in pancreatic beta-cell
- 41 lipotoxicity.
- 42
- 43
- 44

45

46 Introduction

47 Increased adiposity is a risk factor for type 2 diabetes. Ectopic fat deposition arises when

- 48 excess lipid is stored in tissues other than adipose tissue, such as the liver, muscle and
- 49 pancreas. Lipid excess in the pancreas is associated with pancreatic beta-cell dysfunction
- 50 and impaired insulin secretion (1-4). In vitro, chronic treatment with the long chain
- 51 saturated fatty acid palmitate has been shown to reduce insulin secretion in human, rat and
- 52 mouse islets (5-7) and pancreatic beta-cell lines (7-10).
- 53 Fatty acid β -oxidation in animals and man is conducted by both peroxisomes and
- 54 mitochondria (11, 12). Peroxisomes have a role in β-oxidation of long and medium chain
- 55 fatty acids, with the intermediate products transported to the mitochondria for complete
- 56 oxidation (12, 13). The first step of peroxisomal β-oxidation generates reactive oxygen
- 57 species (ROS), principally hydrogen peroxide (H₂O₂). In the majority of cells, this is
- 58 catabolised by oxidoreductase catalase. However, pancreatic β-cells are essentially deficient
- in this enzyme (14-16) leaving them at risk of lipotoxicity from excess H_2O_2 production.
- 60 Elsner and colleagues demonstrated that peroxisomes are a major source of H₂O₂ following
- 61 palmitate treatment of insulin secretory cells. Overexpression of catalase in peroxisomes
- 62 and in the cytosol decreased ROS generation by both the peroxisomes and the
- 63 mitochondria, and led to an improvement in cell viability (17). It remains to be shown,
- 64 however, whether targeted decrease in peroxisome ROS generation specifically improves
- 65 pancreatic beta-cell function in the presence of palmitate.

66 To address this question, we developed a model of targeted peroxisome depletion in MIN6

- 67 cells. Peroxisome proliferation occurs by de novo generation from the endoplasmic
- 68 reticulum and through the division of pre-existing peroxisomes that involves Pex11 proteins
- 69 (18-21). Pex11 β is a protein responsible for the constitutive turnover of peroxisomes and
- 70 *Pex11*β knockout mice have decreased peroxisome abundance (22-24). Through siRNA
- 71 silencing of the *Pex11*β gene we decreased peroxisome abundance and ROS generation in
- 72 MIN6 cells, and found improved beta-cell function in the presence of palmitate.

74 Materials and Methods

75 Cell Culture and Palmitate Medium

- 76 MIN6 cells were donated by Dr Catherine Arden (Diabetes Research Group, Newcastle
- 77 University, UK) and experiments were performed with cells of passage 23-30. MIN6 cells
- 78 were cultured in DMEM containing 4500mg/L glucose, L-glutamine and sodium bicarbonate
- 79 (Sigma), and supplemented with 15% FBS (Life Technologies), 1% Penicillin/Streptomycin
- 80 (Life Technologies), and 0.0005% β-mercaptoethanol (Sigma). Cells were incubated at 37°C,
- 81 5% CO₂ and passaged when 70-80% confluent. For relevant experiments, MIN6 cells were
- 82 incubated with 250μM palmitate conjugated to BSA for the final 48hrs before end point
- 83 measurements were taken. Palmitate was dissolved in deionised water at 70°C before BSA
- 84 (dissolved in PBS) was added to give a final 4mM stock palmitate solution with a 5:1 ratio,
- 85 BSA:Palmitate. The palmitate stock was diluted in supplemented DMEM to the final
- 86 concentration before treatment.

87 Transfection with siRNA against *Pex11*β

- 88 MIN6 cells were transfected using the Neon Transfection System (Life Technologies) as
- 89 previously described (25). Two predesigned Ambion siRNA probes against *Pex11*β, s71497
- 90 and s71499 (Life Technologies), and a Scrambled siRNA negative control (Life Technologies)
- 91 were used for the transfection at a concentration of 100nM. The siRNA sequences for the
- 92 Pex11β probes were as follows: s71497, 5'-UCAUGAAUCUGAGCCGUGAtt-3'; 3'-
- 93 UCACGGCUCAGAUUCAUGAtg-5', and s71499, 5'- CAACCGAGCCUUGUACUUUtt-3'; 3'-
- 94 AAAGUACAAGGCUCGGUUGag-5'.

95 Real-time PCR

96 72hr or 96hr after transfection, RNA was extracted using GenElute™ Mammalian Total RNA

- 97 Miniprep Kit (Sigma) according to the manufacturer's instructions. Following quantification
- 98 of the RNA on a NanoDrop 2000 Spectrophotometer (Thermoscientific), cDNA was
- 99 synthesised using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems),
- 100 according to the manufacturer's instructions. Real-time PCR was carried out on
- 101 LightCycler[®]480 (Roche) using SYBR-green. Predesigned QuantiTect[®] Primer Assays (Qiagen)
- 102 were used for all genes: $Pex11\beta$ and Ykt6. Ykt6 was used as the reference gene. The PCR
- 103 reactions were carried out using LightCycler 480 SYBR green I mastermix (Roche). Results
- 104 were analysed using the comparative $C_T (\Delta \Delta C_T)$ method.
- 105

106 Immunofluorescence

107 MIN6 cells grown directly onto sterile cover slips were washed with PBS then fixed with 4% 108 paraformaldehyde for 20 minutes at room temperature. Cells were permeabilised with 0.2% 109 t-octylphenoxy-polyethoxyethanol (Triton x-100, Sigma) for 45 minutes. Coverslips were incubated with 20% FBS in PBS for 1 hour at room temperature to block non-specific 110 binding. Cells were incubated with 1:600 dilution of rabbit anti-PMP-70 (Abcam) in 0.05% 111 FBS in PBS at 20-22°C for 1 hour. Cells were then washed with PBS, and incubated with 112 1:300 dilution of anti-rabbit Alexa Fluor[®] 546 (Life Technologies) in 0.05% FBS in PBS for one 113 114 hour at room temperature in the dark. The cover slips were then washed again in PBS 115 before mounting on slides with Vectashield Mounting Medium with DAPI (Vector). Slides 116 were visualised on a Zeiss LSM 780 confocal microscope. Quantification of the images was 117 calculated as the number of peroxisomes per area of the image that was covered by cells. Western Blot 118 119 Cells were harvested in protein extraction buffer (100mM Tris-Cl, pH 7.4, 100mM KCl, 1mM 120 EDTA , 25mM KF, 0.1% Triton X-100, 0.5mM sodium orthovanadate, 1x protease inhibitor 121 cocktail (Thermo Scientific)) and sonicated for approximately 10 seconds at 5µm amplitude. 122 Protein concentrations were determined using Coomassie blue, and read on a spectrophotometer at 595nm. 10µg protein was boiled for 5 min with sample buffer 123 124 (62.5mM Tris-HCl pH 6.8, 2% SDS, 10% Glycerol, 0.002% Bromo-phenol blue, 5% 2-125 mercaptoethanol) before being separated on a 10% SDS-PAGE gel. The separated proteins 126 were electrotransferred onto nitrocellulose membranes before being blocked for 1hr in TBS-127 Tween (65mM Tris-HCl, pH 7.4, 150mM NaCl, 0.1% Tween) containing 5% Marvel milk 128 powder. Following incubation with the appropriate primary and secondary antibodies in 1% 129 Marvel, detection was carried out with the addition of enhanced chemiluminescent solution (Thermo Fisher Scientific), and exposure of the nitrocellulose membrane to X-ray film. PMP-130 131 70 antibody was used at a 1.1000 dilution, and β -actin at a 1:10,000 dilution. Quantification of the protein bands was carried out using a GS-800 Calibrated Densitometer (BioRad) and 132 133 the BioRad software Quantity One 4.2.3. 134 **Glucose Stimulated Insulin Secretion (GSIS)**

135 The method for carrying out GSIS was adapted from Ishihara et al. 1994 (26). Cells were

- 136 starved for 30 mins with Krebs-Hepes buffer (119mM NaCl, 4.74mM KCl, 2.54mM CaCl₂,
- 137 1.19mM MgCl₂, 1.19mM KH₂PO₄, 25mM NaHCO₃, 10mM Hepes, 0.5% BSA pH 7.4), before

- being incubated with Krebs-Hepes buffer for a further 1 hour with either 3mM (basal), or
- 139 25mM (stimulating) glucose concentrations. Following incubation, supernatants were
- 140 collected and insulin secretion determined using an Insulin ELISA kit (Mercodia) according to
- 141 the manufacturer's instructions. Insulin secretion was normalised to total protein content.

142 Insulin Content

Following GSIS with 3mM glucose, cells were washed with PBS and harvested in 50µl dH₂O before being sonicated. 150µl acid ethanol (0.18 M HCl in 100% ethanol) was added to the samples and sonicated further. Samples were then stored at 4°C for 12 hours before insulin content was analysed by insulin ELISA using at least 1.100 dilution. Insulin content was normalised to total protein content.

148 **Fatty acid oxidation**

149 96hrs post transfection which included 48hrs palmitate incubation, fatty acid oxidation was assessed by using the Seahorse XF24 Analyzer (Agilent Technologies) to measure 150 151 mitochondrial respiration. Media was replaced with basic media containing 3% FBS and 152 2mM L-glutamine with or without 250 μ M palmitate, and cells were placed in a CO₂ free 153 incubator for 1hr. Oxygen consumption rates (OCR) were used to assess mitochondrial 154 respiration by measurement before and after the injection of compounds that inhibit 155 different mitochondrial complexes: 1µg/ml Oligomycin to inhibit Complex V (ATP synthase) 156 which inhibits the generation of mitochondrial ATP, 2µM and 3.5µM of carbonyl cyanide p-157 trifluoromthoxy-phenylhydrazone (FCCP) which uncouples respiration, and finally Antimycin A, a mitochondrial complex III (Ubiquinol-Cytochrome c Reductase) inhibitor; which, by 158 159 preventing electron transfer, results in the abolishment of ATP synthesis and respiration. 160 Basal mitochondrial respiration = basal oxidation - non-mitochondrial oxidation. ATP 161 synthesis by oxidative phosphorylation = ((Basal oxidation - non-mitochondrial oxidation) -(oligomycin inhibited oxidation - non-mitochondrial oxidation)) multiplied by 2.5 (the 162 163 established phosphate/oxygen ratio for oxidation of palmitate (27)), and further multiplied 164 by 2 (accounting for the 2 oxygen atoms per oxygen molecule).

165 Reactive oxygen species (ROS) detection

166 96hrs post transfection which included 48hrs palmitate incubation, ROS were detected

- using 2',7' –dichlorofluorescin diacetate (DCFDA). ROS such as hydrogen peroxide, peroxyl
- 168 radicals, and peroxynitrile anions can be detected in live cells when DCFDA is oxidised by the

- 169 ROS to form the fluorescent dye DCF (28). Cells were washed with PBS and 20µM DCFDA
- added. Cells were incubated at 37°C, 5% CO₂ for 45 minutes. Cells were washed twice with
- 171 PBS and then incubated in supplemented PBS (90% PBS; 10% FBS) for 30 minutes.
- 172 Fluorescence was recorded (Ex/Em = 485/535). Results were corrected for protein
- 173 concentration.

174 Statistical Analysis

- 175 All statistical analysis was carried out using Graphpad Prism 7 (GraphPad Software, San
- 176 Diego, California, USA). Data are presented as mean ± SEM (standard error of the mean).
- 177 Statistical significance was tested through use of One way ANOVA followed by an unpaired
- t-test. Results were considered to be significant when the probability (p) value was <0.05.

180 Results

181 Palmitate treatment and cell viability

- 182 The first step was to investigate the effects of 250µM palmitate on cell viability and
- apoptosis in MIN6 cells. Following treatment with 250µM palmitate for 48hrs, LDH release
- and caspase 3/7 activity were measured as indices of cell viability and apoptosis,
- respectively. There were no differences in LDH release or caspase 3/7 activity between the
- palmitate treated and BSA control cells (S Fig 1). Under the same conditions, we showed
- 187 that insulin secretion at 25mM glucose was decreased by >50% in palmitate treated cells
- 188 compared with the BSA controls; 2.45±0.41 and 5.27±0.83 ng insulin/µg protein respectively
- 189 (P<0.05) (S Fig 1). Taken together, these data show that treatment with 250µM palmitate
- 190 for 48hours impaired insulin secretory response but with no effect on cell viability.
- 191

192 *Pex11*β knockdown decreases PMP-70 protein expression

- 193 MIN6 cells were transfected using siRNA probe s71497 against *Pex11*β. At 96hr post
- 194 transfection, *Pex11* β gene expression was significantly decreased by \geq 80% (Fig 1A) with
- 195 compared with the scrambled negative control (P<0.001). PMP-70 is a major component of
- the peroxisome membrane and is used to measure peroxisome abundance (17, 29). At
- 197 96hrs post-transfection, there was a 30% decrease in PMP-70 expression relative β-actin (Fig
- 198 1B) in the *Pex11*β knockdown cells compared with the scrambled controls (p<0.001). Fig 1C
- is a representative blot of PMP-70 expression 96hrs post transfection with 2 probes, s71497
- and s71499. Only probe s71497 led to decreased PMP-70 expression and was therefore
- 201 used for subsequent *Pex11*β knockdown experiments.
- 202

203 Fig 1. Pex11ß knockdown and PMP-70 expression in MIN6 cells. MIN6 cells were 204 transfected with probes (s71497) against *Pex11* β or scrambled control. **A**) *Pex11* β mRNA 205 expression was measured after 96hrs by relative quantification using the reference gene Ykt6. The graph shows the mean ± SEM for 3 separate experiments carried out for 3 206 207 separate transfections (n=9), *** p<0.001. B) PMP-70 protein expression relative to β-actin 208 expression was assessed at 96 hrs following *Pex11*β mRNA knockdown. The graph shows the 209 mean \pm SEM for 3 separate experiments were carried out for 2 separate transfections (n=6), 210 **p<0.01. For both A) and B), data are normalised to the scrambled control. C) A 211 representative blot of PMP-70 and β -actin expression 96 hrs post-transfection

(Scr=scrambled control, 99=probe s71499 and 97=probe s71497). Decreased PMP-70
expression was not achieved with s71499, so probe s71497 was used for all subsequent
experiments.

215

To further investigate peroxisome abundance 96hrs post-transfection, cells were seeded
onto coverslips and stained for PMP-70. *Pex11*β knockdown cells had fewer peroxisomes
compared with the scrambled control cells (Figs 2A to 2D), corroborating the western
blotting results. Analysis and quantification of the images showed a significant decrease of
PMP-70 expression in *Pex11*β knockdown cells compared with the scrambled controls
(P<0.05; Fig 2E).

222

223 Fig 2. Immunofluorescent visualization of peroxisomes following *Pex11*β knockdown.

MIN6 cells were stained for PMP-70 as a marker of peroxisomes (red) 96hrs after
transfection with the s71497 siRNA probe against *Pex11*β. DAPI was used for nuclear
counterstaining (blue). A) and B) show cells transfected with the probe against *Pex11*β,
while C) and D) are cells transfected with scrambled control. For the quantification of
peroxisomes E) 9 images from a single transfection were analysed from 4 separate
transfections and the number of peroxisomes per area of the image covered by the cells
was calculated. Data are normalised to scrambled control and presented as mean ± SEM, *

- 231 p<0.05.
- 232 Having established that peroxisome abundance was decreased 96 hrs post *Pex11*β
- knockdown, all subsequent experiments followed the same design. 48hrs post transfection,
- 234 MIN6 cells were incubated with either 250µM palmitate or BSA control for a further 48hrs.
- At 96 hrs post transfection, the relevant measure was made (eg ROS generation, GSIS).
- 236

237 *Pex11*β knockdown does not alter mitochondrial respiratory function

- 238 Oxygen consumption rate (OCR) was measured in MIN6 cells following siRNA transfection
- and treatment with palmitate using the Seahorse XF24 Analyzer (Fig 3A). In *Pex11*β
- 240 knockdown cells, palmitate treatment increased ATP synthesis by oxidative phosphorylation
- 241 (Fig 3B) and basal mitochondrial OCR (Fig 3C) compared with the BSA controls (both,
- p<0.01). The same pattern was seen in the scrambled controls treated with palmitate, with

a trend for an increase in both ATP synthesis and basal OCR. However, there were no
differences between the *Pex11*β knockdown and scrambled control cells for ATP synthesis
or basal mitochondrial OCR in the presence of palmitate. These data indicate that
mitochondrial respiratory function in the presence of palmitate was not affected by
peroxisome depletion.

Fig 3.Palmitate treatment and mitochondrial respiratory function following Pex11ß 249 250 knockdown. 48hrs post transfection MIN6 cells were incubated with 250µM palmitate or 251 BSA control for a further 48hrs. Following this, media was replaced with basic seahorse 252 media containing palmitate and cells were incubated in a CO_2 free incubator for 1hr prior to 253 measuring oxygen consumption rate using the Seahorse XF24 Analyzer. In order to assess 254 fatty acid oxidation, A) mitochondrial respiration was analysed by injections of compounds 255 known to alter mitochondrial function: Oligomycin, FCCP, and Antimycin A. B) ATP synthesis 256 by oxidative phosphorylation (OXPHOS) and C) Basal OCR were calculated as previously 257 described. Data from 2 separate experiments each with 5 separate transfections were 258 normalised to total protein content and expressed as pMoles/min/µg protein. Data are 259 presented as mean±SEM. **p<0.01 palmitate vs BSA control.

260

261 *Pex11*β knockdown decreases palmitate induced ROS production

Following treatment with 250μM palmitate or BSA control for 48hr, ROS production was
measured in the transfected MIN6 cells using the dye DCFDA (Fig 4). In both *Pex11*β
knockdown and scrambled control cells, palmitate significantly increased ROS production
(P<0.001). In the presence of palmitate, ROS levels were markedly lower in the *Pex11*β
knockdown cells compared with the scrambled controls (P<0.001).

Fig 4. Palmitate treatment and ROS production following *Pex11*β knockdown. 48hrs post
transfection MIN6 cells were treated with either 250μM palmitate or BSA for a further 48hrs
in medium containing 25mM glucose. The ROS detection dye DCFDA was added to the cells
and ROS determined in triplicate for each transfection. The figure shows ROS in MIN6 cells
transfected with *Pex11*β knockdown or scrambled siRNA and incubated in palmitate or BSA
for 48hrs. Data from 6 separate transfections are normalised to total protein content. Data
are presented as mean±SEM. ***p<0.001

274 *Pex11*β knockdown reverses the inhibitory effect of palmitate in GSIS

275 Following treatment with 250µM palmitate or a BSA control for 48hrs, GSIS was determined 276 96 hrs post-transfection (Fig 5A). At 25mM glucose, palmitate treatment decreased GSIS in the scrambled control cells (2.54 \pm 0.25 vs 7.07 \pm 0.83 ng/hr/µg protein; palmitate vs BSA; 277 278 P<0.001). Palmitate treatment had a similar but diminished inhibitory effect in the Pex11β 279 knockdown cells (4.04±0.46 vs 6.40±1.02 ng/hr/µg protein; palmitate vs BSA). In the presence of palmitate, GSIS was significantly higher in the *Pex11*β knockdown versus 280 281 scrambled control cells (4.04±0.46 vs 2.54±0.25 ng insulin/hr/µg protein; P<0.05). These 282 data show that the inhibitory effect of palmitate on GSIS was less pronounced following 283 peroxisome depletion.

284

285 Fig 5. Palmitate treatment and insulin secretion and content following *Pex11*β knockdown

48hrs post transfection, MIN6 cells were treated with 250µM palmitate or BSA control for a
further 48hrs. Cells were then stimulated with either 3mM or 25mM glucose. A) Insulin
secretion and B) insulin content were determined, and data from 3 separate experiments
carried out in triplicate presented as mean±SEM. *p<0.05, **p<0.01, ***p<0.001

290

291 *Pex11*β knockdown reverses the adverse effect of palmitate on insulin content

292 We next investigated whether Pex11^β knockdown altered intracellular insulin content (Fig 293 5B). At 25mM glucose, insulin content was decreased by >80% in scrambled siRNA control 294 cells treated with palmitate versus BSA control (10.78±1.37 and 61.67±10.78 ng insulin/µg 295 protein, P<0.001). Similarly, palmitate treatment significantly decreased insulin content in 296 the *Pex11*β knockdown cells (18.92±1.70 and 87.71±10.50 ng insulin/µg protein, P<0.001). 297 However, insulin content was greater in *Pex11* knockdown cells compared with the 298 scrambled control cells in the presence of palmitate (18.92±1.70 vs 10.78±1.37 ng insulin/µg 299 protein, P<0.01). These data show that the effect of palmitate to decrease insulin content 300 was less pronounced in the *Pex11* knockdown cells.

301

302

304 Discussion

We found that *Pex11*β knockdown decreased peroxisome abundance, decreased palmitate
 mediated ROS generation, and reversed the inhibitory effect of palmitate on GSIS. These
 beneficial changes were independent of mitochondrial respiratory function which was
 unaffected by *Pex11*β knockdown. Our investigations have established that targeted
 peroxisome depletion counteracts the adverse effects of palmitate on pancreatic beta-cell
 secretory function.

It is well established that chronic palmitate treatment decreases GSIS (5, 7, 8, 30). Watson 311 et al found that 48hours treatment of MIN6 cells with 400µM palmitate decreased GSIS but 312 313 also increased the pro-apoptotic marker caspase 3/7 activity (8). In addition, studies using 314 primary rat islets have shown that 500µM palmitate treatment for 48 hours was cytotoxic 315 with around 25% of cells damaged (31). Based on these findings we elected to use 250µM 316 palmitate treatment for 48hours, and found that under these conditions there was a clear 317 decrease in GSIS but with no evidence of increased cell damage or apoptosis relative to the 318 BSA control.

Both peroxisomes and mitochondria are in involved in the metabolism and oxidation of

320 palmitate and related long-chain fatty acids (12). Peroxisome β -oxidation generates H_2O_2

321 and shortens the fatty acid chain length prior to transfer to the mitochondria for complete

322 oxidation and ATP generation. We first explored whether $Pex11\beta$ knock down and

decreased peroxisome abundance altered mitochondrial respiratory function. As shown in

Fig 3, palmitate increased basal mitochondrial OCR and ATP generation to a comparable

degree in the *Pex11*β knockdown and scrambled control cells. We therefore conclude that

the beneficial effects of *Pex11*β knockdown and peroxisome depletion on beta-cell function

327 were independent of changes in mitochondrial respiratory function.

328 We next examined ROS generation following palmitate treatment. As shown in Fig 4,

palmitate treatment increased ROS generation, but this was markedly lower in the *Pex11*β

330 knockdown compared with the scrambled control cells. This is consistent with the

331 observation that peroxisomes are a major source of H₂O₂ production in insulin producing

cells (17). It has been proposed that H_2O_2 produced by the peroxisomes may contribute to

333 lipotoxicity due to the low levels of catalase expressed in pancreatic beta-cells (14-16). The

over-expression of catalase in peroxisomes and the cytosol was found to decrease H_2O_2

335 generated by both the peroxisomes and the mitochondria, and to protect against palmitate

toxicity in a rat beta-cell line and isolated rat islets (17). However, the relative contributions

of the peroxisomes and mitochondria to the ROS mediated cytotoxicity was not be defined.

Through targeted *Pex11*β knockdown and peroxisome depletion we have extended these

339 findings and identified a clear and independent role for peroxisomes in palmitate mediated

340 pancreatic beta-cell dysfunction.

341 It is recognised that ROS and specifically H₂O₂ can adversely affect beta-cell function. Insulin

342 secretion decreased from rat pancreatic islets when exposed to low H₂O₂ concentrations

343 similar to that of physiological levels. It was found that this was through the reduction of

344 [Ca²⁺]_i oscillation amplitude, which in turn inhibited GSIS (34). These observations suggest

345 that palmitate increases H_2O_2 production from peroxisomes which, through reduced $[Ca^{2+}]_i$

346 oscillation amplitude, inhibit the insulin secretory response to glucose.

347 Previous studies have reported decreased insulin content in rodent and human pancreatic

348 beta-cells after palmitate treatment (32, 33), with evidence that the mechanism involves

decreased insulin translation (33). As shown in Fig 5B, palmitate decreased insulin content in

both *Pex11*β knock down and control cells at high glucose, but this was less pronounced in

351 the *Pex11* β knock down cells. It is not clear whether ROS and specifically H₂O₂ exert an

inhibitory effect on insulin synthesis as well as secretion. Nonetheless, our findings show

353 that *Pex11*β knockdown and decreased peroxisome abundance reverses the adverse effects

of palmitate on both insulin secretion and insulin content.

355 Our results support the concept that peroxisomes are involved in lipotoxicity and pancreatic 356 beta-cell dysfunction, and thereby might well contribute to the pathogenesis of type 2 357 diabetes. However, exploring peroxisomes as potential targets for therapies that counteract 358 the impact of lipotoxicity on beta-cell function requires careful consideration. This follows a 359 recent study that described a beta-cell specific Pex5 knockout mouse (35). Pex5 is required 360 for the import into the peroxisome of the majority of the enzymes essential for lipid 361 metabolism. While there was evidence of *decreased* GSIS, this appears to be a model of severe peroxisome dysfunction. First, the beta-cell specific Pex5 knockout resulted in a 5 362 fold increase in long chain fatty acid levels in the systemic circulation. Second, the 363 phenotype extended beyond peroxisome dysfunction, with evidence of mitochondrial 364 365 dysfunction, increased beta-cell apoptosis and decreased beta-cell mass. So while partial 366 peroxisome depletion appears to improve beta-cell function in the presence of palmitate,

- 367 there is the risk that more severe peroxisome dysfunction might trigger secondary off-target
- 368 changes and an overall impairment of beta-cell function.
- 369 In conclusion, we have shown that $Pex11\beta$ knockdown decreased peroxisome abundance,
- 370 decreased palmitate mediated ROS generation, and reversed the inhibitory effect of
- 371 palmitate on GSIS. This highlights a potential role of peroxisomes in pancreatic beta-cell
- 372 lipotoxicity and the pathogenesis of type 2 diabetes.
- 373

374 Authors Contributions

- 375 HRB, DG and MW conceived and designed the study. HRB, CT, AEB, SM, AH, AR and MvG
- 376 conducted the experiments, and generated and analysed the data. All authors contributed
- to data interpretation and the writing of the paper.

378 References

Cusi K. The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2
 Diabetes. Current Diabetes Reports. 2010;10(4):306-15.

Kusminski C, Shetty S, Orci L, Unger R, Scherer P. Diabetes and apoptosis: lipotoxicity.
 Apoptosis. 2009;14(12):1484-95.

383 3. Unger RH, Zhou YT. Lipotoxicity of beta-cells in obesity and in other causes of fatty
384 acid spillover. Diabetes. 2001;50(suppl 1):S118.

Schrauwen P, Hesselink MKC. Oxidative Capacity, Lipotoxicity, and Mitochondrial
 Damage in Type 2 Diabetes. Diabetes. 2004;53(6):1412-7.

Hoppa MB, Collins S, Ramracheya R, Hodson L, Amisten S, Zhang Q, et al. Chronic
 Palmitate Exposure Inhibits Insulin Secretion by Dissociation of Ca2+ Channels from
 Secretory Granules. Cell Metabolism. 2009;10(6):455-65.

Zhou YP, Grill V. Long term exposure to fatty acids and ketones inhibits B-cell
 functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab.
 1995;80(5):1584-90. Epub 1995/05/01.

393 7. Sun Y, Ren M, Gao G-q, Gong B, Xin W, Guo H, et al. Chronic palmitate exposure
394 inhibits AMPK[alpha] and decreases glucose-stimulated insulin secretion from [beta]-cells:
395 modulation by fenofibrate. Acta Pharmacol Sin. 2008;29(4):443-50.

Watson ML, Macrae K, Marley AE, Hundal HS. Chronic Effects of Palmitate Overload
 on Nutrient-Induced Insulin Secretion and Autocrine Signalling in Pancreatic MIN6 Beta
 Cells. PLoS ONE. 2011;6(10):e25975.

Section 29. Choi S-E, Lee Y-J, Jang H-J, Lee K-W, Kim Y-S, Jun H-S, et al. A chemical chaperone 4PBA ameliorates palmitate-induced inhibition of glucose-stimulated insulin secretion (GSIS).
Archives of Biochemistry and Biophysics. 2008;475(2):109-14.

402 10. Kristinsson H, Smith DM, Bergsten P, Sargsyan E. FFAR1 is involved in both the acute
403 and chronic effects of palmitate on insulin secretion. Endocrinology. 2013;154(11):4078-88.
404 Epub 2013/09/17.

405 11. Fidaleo M. Peroxisomes and peroxisomal disorders: The main facts. Experimental406 and Toxicologic Pathology. 2009;62(6):615-25.

407 12. Wanders RJA, Waterham HR. Biochemistry of mammalian peroxisomes revisited.408 Annual Review of Biochemistry. 2006;75:295-332.

409 13. Wanders RJA, Ferdinandusse S, Brites P, Kemp S. Peroxisomes, lipid metabolism and
410 lipotoxicity. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids.
411 2010;1801(3):272-80.

412 14. Gehrmann W, Elsner M, Lenzen S. Role of metabolically generated reactive oxygen
413 species for lipotoxicity in pancreatic β-cells. Diabetes, Obesity and Metabolism.
414 2010 12 140 50

414 2010;12:149-58.

415 15. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in

416 pancreatic islets compared with various other mouse tissues. Free Radical Biology and
417 Medicine. 1996;20(3):463-6.

Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation Between Antioxidant Enzyme Gene
Expression and Antioxidative Defense Status of Insulin-Producing Cells. Diabetes.
1997;46(11):1733-42.

421 17. Elsner M, Gehrmann W, Lenzen S. Peroxisome-Generated Hydrogen Peroxide as

422 Important Mediator of Lipotoxicity in Insulin-Producing Cells. Diabetes. 2011;60(1):200-8.

- 423 18. Huybrechts SJ, Van Veldhoven PP, Brees C, Mannaerts GP, Los GV, Fransen M.
- 424 Peroxisome Dynamics in Cultured Mammalian Cells. Traffic. 2009;10(11):1722-33.

425 19. Tabak HF, Murk JL, Braakman I, Geuze HJ. Peroxisomes Start Their Life in the 426 Endoplasmic Reticulum. Traffic. 2003;4(8):512-8. 427 20. Schrader M, Bonekamp NA, Islinger M. Fission and proliferation of peroxisomes. 428 Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2012;1822(9):1343-57. 429 21. Lazarow PB, Fujiki Y. Biogenesis of peroxisomes. Annu Rev Cell Biol. 1985;1:489-530. 430 Epub 1985/01/01. 431 22. Schrader M, Reuber BE, Morrell JC, Jimenez-Sanchez G, Obie C, Stroh TA, et al. 432 Expression of PEX11{beta} Mediates Peroxisome Proliferation in the Absence of Extracellular 433 Stimuli. Journal of Biological Chemistry. 1998;273(45):29607-14. 434 Li X, Baumgart E, Morrell JC, Jimenez-Sanchez G, Valle D, Gould SJ. PEX11{beta} 23. 435 Deficiency Is Lethal and Impairs Neuronal Migration but Does Not Abrogate Peroxisome 436 Function. Mol Cell Biol. 2002;22(12):4358-65. 437 24. Li X, Gould SJ. PEX11 Promotes Peroxisome Division Independently of Peroxisome 438 Metabolism. The Journal of Cell Biology. 2002;156(4):643-51. 439 25. Nile DL, Brown AE, Kumaheri MA, Blair HR, Heggie A, Miwa S, et al. Age-related 440 mitochondrial DNA depletion and the impact on pancreatic Beta cell function. PLoS One. 441 2014;9(12):e115433. Epub 2014/12/23. 442 Ishihara H, Asano T, Tsukuda K, Katagiri H, Inukai K, Anai M, et al. Overexpression of 26. 443 hexokinase I but not GLUT1 glucose transporter alters concentration dependence of 444 glucose-stimulated insulin secretion in pancreatic beta-cell line MIN6. Journal of Biological 445 Chemistry. 1994;269(4):3081-7. 446 27. Mookerjee SA, Goncalves RLS, Gerencser AA, Nicholls DG, Brand MD. The 447 contributions of respiration and glycolysis to extracellular acid production. Biochimica et 448 Biophysica Acta (BBA) - Bioenergetics. 2015;1847(2):171-81. 449 28. Chwa M, Atilano SR, Reddy V, Jordan N, Kim DW, Kenney MC. Increased Stress-450 Induced Generation of Reactive Oxygen Species and Apoptosis in Human Keratoconus 451 Fibroblasts. Investigative Ophthalmology & Visual Science. 2006;47:1902-10. 452 29. Gehrmann W, Elsner M. A specific fluorescence probe for hydrogen peroxide 453 detection in peroxisomes. Free Radic Res. 2011;45(5):501-6. 454 Kelpe CL, Moore PC, Parazzoli SD, Wicksteed B, Rhodes CJ, Poitout V. Palmitate 30. 455 Inhibition of Insulin Gene Expression Is Mediated at the Transcriptional Level via Ceramide 456 Synthesis. Journal of Biological Chemistry. 2003;278(32):30015-21. 31. 457 Hellemans K, Kerckhofs K, Hannaert J-C, Martens G, Van Veldhoven P, Pipeleers D. 458 Peroxisome proliferator-activated receptor α–retinoid X receptor agonists induce beta-cell 459 protection against palmitate toxicity. FEBS Journal. 2007;274(23):6094-105. 460 32. Krizhanovskii C, Fred RG, Oskarsson ME, Westermark GT, Welsh N. Addition of 461 exogenous sodium palmitate increases the IAPP/insulin mRNA ratio via GPR40 in human 462 EndoC-betaH1 cells. Upsala journal of medical sciences. 2017;122(3):149-59. Epub 463 2017/10/06. 464 33. Li Z, Zhou M, Cai Z, Liu H, Zhong W, Hao Q, et al. RNA-binding protein DDX1 is 465 responsible for fatty acid-mediated repression of insulin translation. Nucleic acids research. 466 2018;46(22):12052-66. Epub 2018/10/09. Rebelato E, Abdulkader F, Curi R, Carpinelli AR. Low doses of hydrogen peroxide 467 34. 468 impair glucose-stimulated insulin secretion via inhibition of glucose metabolism and 469 intracellular calcium oscillations. Metabolism: clinical and experimental. 2010;59(3):409-13.

470 Epub 2009/10/06.

35. Baboota RK, Shinde AB, Lemaire K, Fransen M, Vinckier S, Van Veldhoven PP, et al.
Functional peroxisomes are required for beta-cell integrity in mice. Molecular metabolism.
2019;22:71-83. Epub 2019/02/24.

474

475 **Supplementary Information:**

476 S Fig 1. The effect of palmitate incubation on insulin secretion and cytotoxicity in MIN6

- 477 **cells.** MIN6 cells were incubated with either 250μM palmitate or BSA control for 48hrs. **A**)
- 478 Cells were challenged with either 3mM or 25mM glucose and insulin secretion was
- 479 measured. Data are from 3 separate experiments carried out in triplicate are presented as
- 480 mean±SEM. **B**) LDH release into the medium and compared with the LDH assay positive
- 481 control. Data are from 3 separate experiments carried out in triplicate are presented as
- 482 mean±SEM. C) Caspase 3/7 activity was measured using the luminescent Caspase-Glo[®] 3/7
- 483 assay. Staurosporine was used as a positive control. Data are from 6 separate experiments
- 484 carried out in triplicate are presented as mean±SEM. *P<0.05, ***P<0.001 vs BSA control.









C)



Figure 2





Probe



Figure 3

Treatment

Treatment







Figure 5



Glucose Concentration